Edison Expands its European Pharmaceutical Coverage by Initiating on MagForce
LONDON, November 27, 2013 /PRNewswire/ –
Edison Investment Research, a leading international investment research firm,
announces the initiation of coverage of MagForce (MF6), a German firm with a European
approved nanotechnology-based therapy to treat brain tumours.
Edison’s report, Coming out in Force, examines MagForce’s ability to execute on its
strategy to increase uptake of its novel NanoTherm therapy, already approved in Europe for
brain cancer. MagForce has worked closely with a number of key opinion leaders to design a
new glioblastoma (GBM) study, starting imminently, to help increase physician acceptance
and awareness of the therapy. It also intends to enter the US market and develop NanoTherm
therapy for prostate cancer. Edison’s risk-adjusted valuation is EUR197m or EUR8.2/share.
For the full report see:
About Edison Investment Research
The launch of coverage on MagForce is part of a programme of research initiations on
bio-pharmaceutical companies exposed to global market opportunities. Edison provides
detailed research coverage on more than 150 pharmaceutical and healthcare companies in
Europe, North America, Australia and New Zealand. Its team of over 100 analysts and
investment professionals works with leading companies, fund managers and investment banks
worldwide to support its capital markets activity. It provides services to more than 400
retained corporate and investor clients from offices in London, New York, Frankfurt,
Sydney and Wellington. All reports Edison publishes are available to download free of
charge from its website http://www.edisongroup.com.
Edison is authorised and regulated by the Financial Services Authority (
http://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). Edison is not an
adviser or broker-dealer and does not provide investment advice. Edison’s reports are not
solicitations to buy or sell any securities.
MagForce is a German firm with a European approved nanotechnology-based therapy to
treat brain tumours. NanoTherm therapy consists of nanoparticle injection into the tumour,
activated by an external magnetic field, producing heat and thermally destroying or
sensitising the tumour.
For more information please contact: Dr Philippa Gardner, Edison Investment Research, +44(0)20-3681-2521 email@example.com
SOURCE Edison Investment Research